← Leaderboards
Kyeong-Ok Chang
University Of Kansas Medical Center
$9,099,203
Attributed
$17,472,732
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,472,732 · 7
By mechanism
R01$11,906,761 · 3
U01$4,900,152 · 1
P20$665,819 · 3
Top collaborators
- William C Groutas16 shared
- Stanley Perlman11 shared
- Terry L Bowlin5 shared
- Linda J. Saif5 shared
- Yunjeong Kim2 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsDisease OutbreaksViralVirus ReplicationIn VivoEnzymesSeriesVaccinesPeptide HydrolasesPre-ClinicalAntiviral AgentsLeadBaseVirusDrug CandidatePermeabilityPreventiveNorovirusCytotoxicityIn VitroAnalogDesignProtease InhibitorOral
Grant awards (24)
Small Molecule Protease Inhibitors against MERS-CoV and Coronaviruses of Pandemic Potential$733,730
R01 · FY2025 · AI · contact PI
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2$731,337
R01 · FY2025 · AI · contact PI
Small Molecule Protease Inhibitors against MERS-CoV and Coronaviruses of Pandemic Potential$773,323
R01 · FY2024 · AI · contact PI
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2$735,037
R01 · FY2023 · AI · contact PI
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2$735,037
R01 · FY2022 · AI · contact PI
Small Molecule Protease Inhibitors against MERS-CoV$728,584
R01 · FY2022 · AI · contact PI
Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-2$774,037
R01 · FY2021 · AI · contact PI
Small Molecule Protease Inhibitors against MERS-CoV$730,761
R01 · FY2021 · AI · contact PI
Small Molecule Protease Inhibitors against MERS-CoV$732,873
R01 · FY2020 · AI · contact PI
Small Molecule Protease Inhibitors against MERS-CoV$734,924
R01 · FY2019 · AI · contact PI
Small Molecule Protease Inhibitors against MERS-CoV$775,916
R01 · FY2018 · AI · contact PI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2018 · AI · contact PI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2017 · AI · contact PI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2016 · AI · contact PI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2015 · AI · contact PI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$784,022
R01 · FY2014 · AI · contact PI
Development of Novel Therapeutic Agents for Norovirus Infection$895,635
U01 · FY2013 · AI · contact PI
Development of Novel Therapeutic Agents for Norovirus Infection$952,801
U01 · FY2012 · AI · contact PI
Development of Novel Therapeutic Agents for Norovirus Infection$1,005,959
U01 · FY2011 · AI · contact PI
Development of Novel Therapeutic Agents for Norovirus Infection$1,027,980
U01 · FY2010 · AI · contact PI
Development of Novel Therapeutic Agents for Norovirus Infection$1,017,777
U01 · FY2009 · AI · contact PI
REPLICATION OF NOROVIRUSES IN CELL CULTURE$253,524
P20 · FY2009 · RR · contact PI
REPLICATION OF NOROVIRUSES IN CELL CULTURE$242,808
P20 · FY2008 · RR · contact PI
REPLICATION OF NOROVIRUSES IN CELL CULTURE$169,487
P20 · FY2007 · RR · contact PI